Canadian Court Upholds Lipitor Patent

Law360, New York (March 21, 2008, 12:00 AM EDT) -- After a series of unfavorable rulings for Pfizer Inc., a Canadian appeals court has upheld the pharmaceutical giant's patent for Lipitor, delivering a setback to Ranbaxy Laboratories Ltd. in its quest to market a generic version of the blockbuster cholesterol drug.

The Federal Court of Appeal of Canada ruled Thursday that Ranbaxy's lower-priced knockoff would not be entitled to regulatory approval until Pfizer's patent expires in July 2010, according to Pfizer.

“This decision sends a strong signal about the importance of protecting intellectual property in Canada,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.